Cochrane · systematic review · CD010060
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
Pattanaik, S, Mavuduru, RS, Panda, A, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
12
No studies
6
Included studies
NR
No studies 6 · 33.3%Ungraded 0 · 0%Very low 0 · 0%Low 8 · 44.4%Moderate 4 · 22.2%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
PDEI compared to placebo for lower urinary tract symptoms consistent with benign prostatic hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IPSS‐total score PDEI vs placebo | no estimate extracted | 11 studies · 4293 participants | Low Downgraded: risk of bias |
BPHII score PDEI vs placebo | no estimate extracted | 8 studies · 3646 participants | Low Downgraded: risk of bias |
Adverse events PDEI vs placebo | RR 1.42 [1.21, 1.67] | 11 studies · 4386 participants | Low Downgraded: risk of bias |
PDEI compared to alpha‐blockers for LUTS associated with BPH
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IPSS‐total score PDEI vs alpha‐blockers | no estimate extracted | 4 studies · 933 participants | Moderate Downgraded: risk of bias |
BPHII score PDEI vs alpha‐blockers | no estimate extracted | 2 studies · 550 participants | Low Downgraded: risk of bias |
Adverse events PDEI vs alpha‐blockers | RR 1.35 [0.8, 2.3] | 4 studies · 786 participants | Low Downgraded: risk of bias |
PDEI plus alpha‐blocker compared to alpha‐blockers alone for LUTS associated with BPH (short‐term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IPSS‐total score PDEI plus alpha‐blocker vs alpha‐blockers alone | no estimate extracted | 4 studies · 193 participants | Low Downgraded: risk of bias |
BPHII score PDEI plus alpha‐blocker vs alpha‐blockers alone | no estimate extracted | NR | No studies |
Adverse effects PDEI plus alpha‐blocker vs alpha‐blockers alone | RR 2.81 [1.53, 5.17] | 4 studies · 194 participants | Moderate Downgraded: risk of bias |
PDEI plus an alpha‐blocker compared to PDEI alone for LUTS associated with BPH (short‐term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IPSS‐total score PDEI plus an alpha‐blocker vs PDEI alone | no estimate extracted | 1 study · 40 participants | Low Downgraded: risk of bias |
BPHII score PDEI plus an alpha‐blocker vs PDEI alone | no estimate extracted | NR | No studies |
Adverse events PDEI plus an alpha‐blocker vs PDEI alone | no estimate extracted | NR | No studies |
PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (short‐term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IPSS‐total score PDEI + 5‐ARI vs 5‐ARI alone | no estimate extracted | 1 study · 695 participants | Moderate Downgraded: risk of bias |
BPHII score PDEI + 5‐ARI vs 5‐ARI alone | no estimate extracted | NR | No studies |
Adverse events PDEI + 5‐ARI vs 5‐ARI alone | no estimate extracted | NR | No studies |
PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (long‐term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IPSS‐total score PDEI + 5‐ARI vs 5‐ARI alone | no estimate extracted | 1 study · 695 participants | Moderate Downgraded: risk of bias |
BPHII score PDEI + 5‐ARI vs 5‐ARI alone | no estimate extracted | NR | No studies |
Adverse events PDEI + 5‐ARI vs 5‐ARI alone | RR 1.07 [0.84, 1.36] | 1 study · 695 participants | Low Downgraded: risk of bias |